Clinical Trials
Our lead candidate, ANG003, is currently being investigated in a large, international Phase 2 study in people ages 12 years and older with cystic fibrosis and exocrine pancreatic insufficiency (NCT07450547). ANG003 will be compared alongside a current standard of care pancreatic enzyme replacement therapy (PERT). Along with safety, changes in fat & nutrient absorption, changes in stool, and changes in gastrointestinal symptoms will be evaluated. Learn more about the study at the Cystic Fibrosis Foundation’s Trial Finder.
“We all work hard at Anagram. However, no one works harder than the people who participate in our studies. Their strength — and that of their families — is what motivates us.”
